OA11871A - Novel pharmaceutical. - Google Patents

Novel pharmaceutical. Download PDF

Info

Publication number
OA11871A
OA11871A OA1200100275A OA1200100275A OA11871A OA 11871 A OA11871 A OA 11871A OA 1200100275 A OA1200100275 A OA 1200100275A OA 1200100275 A OA1200100275 A OA 1200100275A OA 11871 A OA11871 A OA 11871A
Authority
OA
OAPI
Prior art keywords
polymorph
provides
compound
polymorph according
containing peaks
Prior art date
Application number
OA1200100275A
Other languages
English (en)
French (fr)
Inventor
Paul David James Blackler
Robert Gordon Giles
Michael John Sasse
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11871(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9909472.4A external-priority patent/GB9909472D0/en
Priority claimed from GBGB9912197.2A external-priority patent/GB9912197D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA11871A publication Critical patent/OA11871A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
OA1200100275A 1999-04-23 2000-04-19 Novel pharmaceutical. OA11871A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9909472.4A GB9909472D0 (en) 1999-04-23 1999-04-23 Novel compounds
GBGB9912197.2A GB9912197D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
OA11871A true OA11871A (en) 2006-03-27

Family

ID=26315460

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100275A OA11871A (en) 1999-04-23 2000-04-19 Novel pharmaceutical.

Country Status (40)

Country Link
US (2) US6815457B1 (no)
EP (3) EP1284268B1 (no)
JP (1) JP2002543075A (no)
KR (1) KR100744359B1 (no)
CN (1) CN1208335C (no)
AP (1) AP1495A (no)
AR (2) AR023564A1 (no)
AT (2) ATE247653T1 (no)
AU (1) AU765498B2 (no)
BG (1) BG65427B1 (no)
BR (1) BR0009934A (no)
CA (1) CA2370258A1 (no)
CO (1) CO5170424A1 (no)
CY (1) CY1107238T1 (no)
CZ (1) CZ20013799A3 (no)
DE (2) DE60004658T2 (no)
DK (2) DK1284268T3 (no)
DZ (1) DZ3155A1 (no)
EA (1) EA004534B1 (no)
ES (2) ES2204557T3 (no)
HK (2) HK1055293A1 (no)
HR (1) HRP20010773B1 (no)
HU (1) HUP0200929A3 (no)
IL (1) IL146110A0 (no)
MA (1) MA26785A1 (no)
MX (1) MXPA01010820A (no)
MY (1) MY128007A (no)
NO (1) NO320589B1 (no)
NZ (1) NZ515163A (no)
OA (1) OA11871A (no)
PE (1) PE20010040A1 (no)
PL (1) PL351686A1 (no)
PT (2) PT1173434E (no)
RS (1) RS50114B (no)
SK (1) SK286423B6 (no)
TR (1) TR200103061T2 (no)
TW (1) TW591027B (no)
UA (1) UA67843C2 (no)
UY (1) UY26120A1 (no)
WO (1) WO2000064892A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
ATE246191T1 (de) * 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
ATE247653T1 (de) 1999-04-23 2003-09-15 Smithkline Beecham Plc Thiazolidindionderivat und seine verwendung als antidiabetikum
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US7241895B2 (en) * 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
MXPA03002580A (es) * 2000-09-26 2003-10-15 Cord Janet I Nuevas formas polimorficas de maleato de 5-(4-(2-(n-metil-n-(2-piridil) amino)etoxi)bencil) tiazolidin-2, 4-diona y proceso para su preparacion.
AU2002352391A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003053962A1 (en) * 2001-12-20 2003-07-03 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10199003I1 (de) 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
MX9603338A (es) 1994-02-10 1997-03-29 Smithkline Beecham Plc Uso de sensibilizadores a la insulina para tratar enfermedades renales.
US20010044458A1 (en) * 1994-02-10 2001-11-22 Smithkline Beechamp P.L.C. Use of insulin sensitisers for treating renal diseases
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
GB9711683D0 (en) 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
KR20080011356A (ko) 1997-06-18 2008-02-01 스미스클라인비이참피이엘시이 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
IL133138A0 (en) 1997-06-18 2001-03-19 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
ATE355840T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
US20020045649A1 (en) * 1997-07-18 2002-04-18 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
ATE247653T1 (de) 1999-04-23 2003-09-15 Smithkline Beecham Plc Thiazolidindionderivat und seine verwendung als antidiabetikum
JP2002543076A (ja) 1999-04-23 2002-12-17 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
ATE246191T1 (de) 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
MXPA03002580A (es) 2000-09-26 2003-10-15 Cord Janet I Nuevas formas polimorficas de maleato de 5-(4-(2-(n-metil-n-(2-piridil) amino)etoxi)bencil) tiazolidin-2, 4-diona y proceso para su preparacion.

Also Published As

Publication number Publication date
TW591027B (en) 2004-06-11
PL351686A1 (en) 2003-06-02
BG65427B1 (bg) 2008-07-31
EA004534B1 (ru) 2004-06-24
DK1173434T3 (da) 2003-12-08
HUP0200929A2 (en) 2002-08-28
CO5170424A1 (es) 2002-06-27
BG106119A (en) 2002-05-31
UY26120A1 (es) 2000-12-29
NO320589B1 (no) 2005-12-27
SK14912001A3 (sk) 2002-02-05
EA200101119A1 (ru) 2002-04-25
TR200103061T2 (tr) 2002-05-21
UA67843C2 (uk) 2004-07-15
AU4130600A (en) 2000-11-10
WO2000064892A3 (en) 2001-01-25
BR0009934A (pt) 2002-06-04
CA2370258A1 (en) 2000-11-02
CN1208335C (zh) 2005-06-29
EP1173434B1 (en) 2003-08-20
KR20020028873A (ko) 2002-04-17
MA26785A1 (fr) 2004-12-20
EP1173434A2 (en) 2002-01-23
ATE247653T1 (de) 2003-09-15
DK1284268T3 (da) 2008-04-28
HK1055293A1 (en) 2004-01-02
HRP20010773B1 (en) 2005-06-30
NO20015149D0 (no) 2001-10-22
US20040092555A1 (en) 2004-05-13
PT1173434E (pt) 2003-12-31
EP1903043A1 (en) 2008-03-26
SK286423B6 (sk) 2008-09-05
RS50114B (sr) 2009-03-25
AU765498B2 (en) 2003-09-18
NZ515163A (en) 2004-02-27
PE20010040A1 (es) 2001-03-10
KR100744359B1 (ko) 2007-07-30
DE60037602T2 (de) 2009-01-08
DZ3155A1 (fr) 2000-11-02
AR023568A1 (es) 2002-09-04
MXPA01010820A (es) 2002-06-04
AP1495A (en) 2005-11-30
HRP20010773A2 (en) 2002-10-31
IL146110A0 (en) 2002-07-25
JP2002543075A (ja) 2002-12-17
DE60004658D1 (de) 2003-09-25
EP1284268B1 (en) 2007-12-26
EP1284268A1 (en) 2003-02-19
ES2298327T3 (es) 2008-05-16
DE60037602D1 (de) 2008-02-07
CZ20013799A3 (cs) 2002-04-17
HUP0200929A3 (en) 2004-03-29
AR023564A1 (es) 2002-09-04
CY1107238T1 (el) 2012-11-21
US6815457B1 (en) 2004-11-09
CN1355801A (zh) 2002-06-26
ES2204557T3 (es) 2004-05-01
DE60004658T2 (de) 2004-06-24
HK1045154A1 (en) 2002-11-15
NO20015149L (no) 2001-12-17
HK1045154B (zh) 2004-06-25
YU75201A (sh) 2004-09-03
PT1284268E (pt) 2008-03-10
ATE382046T1 (de) 2008-01-15
WO2000064892A2 (en) 2000-11-02
MY128007A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
US7368574B2 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
OA11871A (en) Novel pharmaceutical.
US6806280B1 (en) Polymorph of 5-[4-[2-(n-methyl-n(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione, maleic acid salt
AU771342B2 (en) Novel pharmaceutical
US7230109B2 (en) 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US7358366B2 (en) Thiazolidinedione derivative and its use as antidiabetic
EP1315721B1 (en) A thiazolidinedione derivative and its use as antidiabetic
US20040038968A1 (en) Thiazolidinedione derivative and its use as antidiabetic
ZA200108722B (en) Thiazolidinedione derivative and its use as antidiabetic.